Covid-19 roundup: Novavax says vaccine shows 'broad cross-reactivity' against Omicron; France cancels order on Merck’s antiviral pill — report
Novavax said Wednesday that initial data suggest its Covid-19 vaccine demonstrated “broad cross-reactivity against Omicron and other circulating variants” after two doses — though neutralization was around 4-fold lower against Omicron compared to the original strain.
As a result, the company says it’s working on an Omicron-specific vaccine and plans to launch clinical studies in the first quarter of 2022.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.